XEMASIN 25MG TABLETS

Xemasin 25mg Tablets is a prescription hormonal anticancer medicine containing exemestane, a steroidal aromatase inhibitor widely used in the treatment of estrogen receptor-positive (ER+) breast cancer in postmenopausal women. This oral therapy plays an important role in hormone-dependent breast cancer management by targeting estrogen production, a key driver of tumor growth.

Exemestane in Xemasin works by irreversibly inhibiting the aromatase enzyme, significantly reducing estrogen levels in the body. Lower estrogen availability helps slow or stop the growth of hormone-sensitive breast cancer cells and supports long-term disease control. Xemasin 25 mg Tablet is commonly prescribed as part of extended adjuvant therapy to improve treatment outcomes.

Manufactured in WHO-GMP certified facilities, Xemasin 25 mg Tablet ensures consistent quality, safety, and therapeutic effectiveness. It is a prescription-only oncology medicine intended for oral use and should be taken strictly under the supervision of a qualified oncologist. Xemasin tablet offers a reliable and clinically proven option for ongoing hormonal therapy in postmenopausal breast cancer patients.

Product Features

• Oral aromatase inhibitor therapy
• Contains Exemestane 25 mg
• Used in hormone-positive breast cancer
• Lowers estrogen production effectively
• Once-daily oral dosing
• Suitable for long-term breast cancer management
• Manufactured under GMP-compliant standards
• Prescription-required oncology medicine

How It Helps

• Reduces estrogen levels to slow hormone-dependent tumor growth
• Blocks the aromatase enzyme involved in estrogen production
• Helps prevent recurrence of ER-positive breast cancer
• Supports effective long-term hormonal therapy under medical supervision